Co-Diagnostics, Inc. (CODX) Q3 2022 Earnings Call Transcript

Nov. 10, 2022 10:41 PM ETCo-Diagnostics, Inc. (CODX)
SA Transcripts profile picture
SA Transcripts
133.88K Followers

Co-Diagnostics, Inc. (NASDAQ:CODX) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET

Company Participants

Dan Bohrer - VP, Finance and Accounting

Dwight Egan - CEO

Brian Brown - CFO

Conference Call Participants

Theodore O'Neill - Litchfield Hills Research

Operator

Good afternoon, and welcome to the Co-Diagnostics, Inc. Third Quarter 2022 Earnings Results Conference Call. [Operator Instructions] Please note, this event is being recorded.

I would now like to turn the conference over to Dan Bohrer, Vice President of Finance and Accounting. Please go ahead.

Dan Bohrer

Thank you. I am Dan Bohrer, and joining me this afternoon are members of the Co-Diagnostics management team, including Dwight Egan, Chief Executive Officer; and Brian Brown, Chief Financial Officer.

We will begin the call with management's prepared remarks and then open up the call to questions from our analysts. Before we begin, we would like to inform the listeners that certain statements made by Co-Diagnostics during the course of this call may constitute forward-looking statements. Any statement about company expectations, beliefs, plans, objectives, assumptions of future events or performance are forward-looking statements.

For example, statements concerning 2022 financial and operational guidance, the development, regulatory clearance, commercialization and features of new products, plans and objectives of management and market trends are all forward-looking statements. This includes statements concerning the company's forthcoming PCR home testing platform, which is subject to FDA review and is not yet available for sale. The company believes these statements are based on reasonable assumptions. However, these statements are not guarantees of performance and involve known and unknown risks and uncertainties that may cause the actual results to be materially different from any future results expressed or implied by such statements. Important factors, which could cause actual results to differ materially from those in these forward-looking statements, are detailed in Co-Diagnostics filings with the SEC.

Recommended For You

Comments

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.